Roche’s Gazyva Extends Leukemia Patients’ Survival

Roche Holding AG’s newly approved medicine Gazyva helped patients with chronic lymphocytic leukemia live almost a year longer without their disease progressing than its top-seller, Rituxan, in a clinical trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.